文献速递胃肠外科肝胆胰外科围术期管理与 ERAS

局部进展期胃食管结合部腺癌新辅助放化疗与化疗的预后比较

Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma.
PubMed 文献 · Br J Surg · 2021-01-01

该回顾性研究纳入2002至2017年单中心775例接受新辅助治疗后手术的局部进展期胃食管结合部腺癌患者,其中650例接受放化疗、125例接受化疗。调整后新辅助放化疗与化疗相比,总生存(HR 1.26,95%CI 0.96-1.67)和无病生存(HR 1.27,95%CI 0.98-1.64)均无显著差异,术后主要并发症和30天死亡率亦无显著差异。

要点

  • 局部进展期GOJ腺癌新辅助放化疗与化疗的OS和DFS无显著差异。
  • 两组术后主要并发症(20.0% vs 17.6%)和30天死亡率(1.7% vs 1.6%)无显著差异。
  • 新辅助放化疗与化疗后复发类型(局部、区域或远处)无差异。

核心结论

  • 对局部进展期胃食管结合部腺癌行手术切除的患者,新辅助放化疗与化疗相比OS和DFS无显著差异。

研究设计与样本

  • 回顾性研究,收集2002至2017年单中心所有接受新辅助治疗后手术的胃食管结合部腺癌患者数据,共775例,其中650例接受新辅助放化疗、125例接受化疗。

主要发现

  • 术后主要并发症放化疗组20.0%、化疗组17.6%,30天死亡率分别为1.7%和1.6%,均无显著差异。
  • 调整后新辅助放化疗与化疗相比,OS的HR为1.26(95%CI 0.96-1.67),DFS的HR为1.27(95%CI 0.98-1.64),均无显著关联。
  • 新辅助放化疗与化疗后复发类型(局部、区域或远处)无差异。
  • 放化疗组白种男性比例更高、病理完全缓解比例更高,弥漫型癌、低分化和神经血管侵犯比例更低。

临床怎么用

  • 对于局部进展期胃食管结合部腺癌,新辅助放化疗与化疗在生存和术后安全性方面未见显著差异,治疗选择可结合患者具体情况个体化。

局限性

  • 为单中心回顾性研究,两组样本量差异较大(650例 vs 125例),可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trials typically group cancers of the gastro-oesophageal junction (GOJ) with oesophageal or gastric cancer when studying neoadjuvant chemoradiation and perioperative chemotherapy, so the results may not be fully applicable to GOJ cancer. Because optimal neoadjuvant treatment for GOJ cancer remains controversial, outcomes with neoadjuvant chemoradiation versus chemotherapy for locally advanced GOJ adenocarcinoma were compared retrospectively. METHODS: Data were collected from all patients who underwent neoadjuvant treatment followed by surgery for adenocarcinoma located at the GOJ at a single high-volume institution between 2002 and 2017. Postoperative major complications and mortality were compared between groups using Fisher's exact test. Overall survival (OS) and disease-free survival (DFS) were assessed by log rank test and multivariable Cox regression analyses. Cumulative incidence functions were used to estimate recurrence, and groups were compared using Gray's test. RESULTS: Of 775 patients, 650 had neoadjuvant chemoradiation and 125 had chemotherapy. These groups were comparable in terms of clinical tumour and lymph node categories, although the chemoradiation group had greater proportions of white men, complete pathological response to chemotherapy, and smaller proportions of diffuse cancer, poor differentiation, and neurovascular invasion. Postoperative major complications (20.0 versus 17.6 per cent) and 30-day mortality (1.7 versus 1.6 per cent) were not significantly different between the chemoradiation and chemotherapy groups. After adjustment, type of therapy (chemoradiation versus chemotherapy) was not significantly associated with OS (hazard ratio (HR) 1.26, 95 per cent c.i. 0.96 to 1.67) or DFS (HR 1.27, 0.98 to 1.64). Type of recurrence (local, regional, or distant) did not differ after neoadjuvant chemoradiation versus chemotherapy. CONCLUSION: In patients undergoing surgical resection for locally advanced adenocarcinoma of the GOJ, OS and DFS did not differ significantly between patients who had neoadjuvant chemoradiation compared with chemotherapy. Treating advanced cancer of the gastro-oesophageal junction (GOJ) poses a challenge given its location in the distal oesophagus and proximal stomach, and whether it should be treated as oesophageal or gastric cancer. Given the indistinct location, it is unclear whether GOJ cancer should be treated with neoadjuvant chemoradiation, which is the treatment of choice for advanced oesophageal cancers, or perioperative chemotherapy, which is the treatment of choice for advanced gastric cancers. Few studies have addressed treatment options specifically for GOJ cancers. This study investigated whether there was a difference in survival between patients with GOJ cancer who were treated with chemoradiation versus chemotherapy.

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Vos EL, Carr RA, Hsu M, et al. Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma. Br J Surg. 2021. PMID: 34476473. doi:10.1093/bjs/znab228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。